Interestingly, LILRB1 gene and protein levels correlate with a shorter progression-free survival and poor clinical outcome in high but not operated intermediate-risk prostate cancer patients, indicating its correlation with tumour grade (126). This evidence concerns the gene LILRB1 and prostate carcinoma.